|
[1]
|
Lazarescu GR,Battista JJ.Analysis of the radiobiolo-gy of Ytterbium-169 and Iodine-125 permanent brachytherapy implants[J].Phys Med Biol,1997,42:1727-1736. |
|
[2]
|
Ling CC.Permanent implams using Au-198,Pd-103 and I-125:Radiobiological considerations based on the linear quadratic model[J].Int J Radiat Oncol Biol Phys,1992,23:81-87. |
|
[3]
|
Kim JH,Hilaris BS.Iodinc-125 sourcc in interstitial tumor therapy[J].Radiology,1975,123:163-169. |
|
[4]
|
Anderson LL,Kuan HM,Ding IY.Clinical dosimetry with I-125[A].In Gorge[ed].Modern interstitial and intracavitary radation cancer management[C].New York:Masson Publishing,1981. |
|
[5]
|
Williamson JF.Physics of brachythcrapy[A].Perez CA,Brady LW[ed].Principles and practice of radia-tion oncology[C].Third Edition,Philadelphia:Lip-pincott-Raven,1997 |
|
[6]
|
Nath R,Anderson LL,Meli JA,et al.Code of prac-tice for brachytherapy physics:Report of the AAPM radation therpy committee task group NO.56[J].Med Phys,1997,24:1557-1579. |
|
[7]
|
Wu A,Zwicker D,Sternick ES.Tumor dose specifi-cation of I-125 seed implants[J].Med Phys,1985,12:27-31. |
|
[8]
|
Chen Y,Stanton RE,Holst RJ,et al.Treatment planning for prostate implant with loose seeds[J].Med Phys,1997,24:1141-1145. |
|
[9]
|
Nath R,Anderson LL,Luxton G,et al.Dosimetry of interstitial brachtherapy sources:Recommendations of the AAPM radiation therapy committee task group NO.43[J].Med Phys,1995,22:209-233. |
|
[10]
|
Williamson JF,Courscy BM,DeWerd LA,et al.Guidence to users of Nycomed Amersham and North American Scientific,Inc,I-125 interstitial sources:Dosimetry and calibration changes:Recommendations of the American Association of physicists in Medicine Radiation Therapy Committee Ad Hoc Subcommittee on low-energy[J].Med Phys,1999,26:570-573. |
|
[11]
|
Kleinberg L,Wallner K,Roy J,et al.Treatment-re-lated srmptoms during the first year following transperineal I-125 prostate implanation[J].Int J Ra-diat Oncol Biol Phys,1994,28:985-990. |
|
[12]
|
Wallner K,Roy J,Harrison L.Low risk of periopera-tive infection without pfophylactic for transperineal prostate brachytherapy[J].Int J Radiat Oncol Biol Phys,1996,36:681-683. |
|
[13]
|
Beyer DC,Priestley JB.Biochemical disease-free sur-vival following I-125 prostate implantation[J].Int J Radiat Oncol Biol Phys,1997,37;559-563. |
|
[14]
|
Ohorio M,Wheler TM,Scardino PT.The new American Joint Committee on Cancer and InternationalUnion Against Cancer TNM classification of prostate cancer[J].Cancer.1994,73:104-114. |
|
[15]
|
Armstrong JG,Anderson LL,Harrison LB.Treat-ment of liver metastases from colorectal cancer with radioactive implants[J].Cancer,1994,73:1800-1804. |
|
[16]
|
Martinez-Monge R,Nag S,Nieroda CA,et al.Io-dine-125 brachytherapy in the treatment of colorectal adenocarcinoma metastic to the liver[J].Cancer,1999,85:1218-1225. |
|
[17]
|
Chen A,Galloway M,Landreneau R,et al.Intraop-erative I-125 brachytherapy for high-risk stage I non-small cell lung carcinoma[J].Int J Radiat Oncol Biol Phys,1999,44:1057-1063. |
|
[18]
|
Mittal BB,Nemcek AA,Sider L.Malignant tumors invading chest wall:Treatment with CT-directed im-plantation of radioactive seeds[J].Radiology,1993,186:901-903. |
|
[19]
|
Schuricht AL,Spitz F,Barbct D,et al.Intraoperative radiotherapy in the combined modality management of pancreatic cancer[J].Am Surg,1998,1043-1049. |
DownLoad: